BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients

Br J Dermatol. 2017 Oct;177(4):e94-e95. doi: 10.1111/bjd.15345. Epub 2017 Aug 30.

Authors

C Vanhaecke¹, F Deilhes², J Chanal^{1

3}, E Regnier-Rosencher¹, F Boitier¹, S Boulinguez², M-F Avril^{1

3}, S Guégan^{1

3}, N Dupin^{1

3}, S Aractingi^{1

3}, N Meyer^{2

4}, N Kramkimel¹

Affiliations

¹ Service de Dermatologie, Hôpital Cochin Tarnier, APHP, 89 rue d'Assas, 75006, Paris, France.
² Service de Dermatologie, Université Paul Sabatier - Toulouse III et Institut Universitaire du Cancer de Toulouse, CHU - LARREY et Oncopole, Toulouse, France.
³ Université Paris Descartes, Paris, France.
⁴ Inserm UMR 1037 - CRCT, Toulouse, France.

PMID: 28129668
DOI: 10.1111/bjd.15345

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Adult
Antineoplastic Agents / therapeutic use*
Carbamates / therapeutic use
Drug Substitution
Humans
Imidazoles / therapeutic use
Indoles / therapeutic use
Melanoma / drug therapy*
Middle Aged
Neoplasm Recurrence, Local / etiology
Oximes / therapeutic use
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Retrospective Studies
Skin Neoplasms / drug therapy*
Sulfonamides / therapeutic use
Vemurafenib
Young Adult

Substances

Antineoplastic Agents
Carbamates
Imidazoles
Indoles
Oximes
Sulfonamides
Vemurafenib
encorafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf
dabrafenib